The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Biosimilar Market Research Report 2024
Synopsis
A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.
Unlike with generic drugs of the more common small-molecule type, biologics generally exhibit high molecular complexity and may be quite sensitive to changes in manufacturing processes. Despite that heterogeneity, all biopharmaceuticals, including biosimilar, must maintain consistent quality and clinical performance throughout their lifecycle.
In this report is a biologic defined as proteins, peptides, hormones or antibody’s drugs production by bio-engineered technology, but does not include a vaccine.
The global Biosimilar market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
China’s core biosimilar players include Qilu Pharmaceutical, Shanghai Henlius and 3SBIO etc. The top 3 companies only hold a share about 61%.
In terms of product, biosimilar monoclonal antibodies is the largest segment, with a share about 85%. And in terms of application, the largest application is cancer，with a share about 50%.
This report aims to provide a comprehensive presentation of the global market for Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar.
Report Scope
The Biosimilar market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilar market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Amgen
Biogen
Novartis
Samsung Bioepis
Viatris
Fresenius Kabi
Celltrion
Cadila Healthcare
Torrent Pharmaceuticals
Boehringer Ingelheim
Qilu Pharmaceutical
Bio-Thera
Zhejiang Hisun
Shanghai Henlius
Innovent Biologics
Jiangsu Hengrui
Gan&Lee
Tonghua Dongbao
United Laboratory
3SBIO
Luye Pharma
Segment by Type
Biosimilar Monoclonal Antibodies
Biosimilar Insulin
Others
Segment by Application
Cancer
Immunological Diseases
Diabetes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biosimilar companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.
Unlike with generic drugs of the more common small-molecule type, biologics generally exhibit high molecular complexity and may be quite sensitive to changes in manufacturing processes. Despite that heterogeneity, all biopharmaceuticals, including biosimilar, must maintain consistent quality and clinical performance throughout their lifecycle.
In this report is a biologic defined as proteins, peptides, hormones or antibody’s drugs production by bio-engineered technology, but does not include a vaccine.
The global Biosimilar market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
China’s core biosimilar players include Qilu Pharmaceutical, Shanghai Henlius and 3SBIO etc. The top 3 companies only hold a share about 61%.
In terms of product, biosimilar monoclonal antibodies is the largest segment, with a share about 85%. And in terms of application, the largest application is cancer，with a share about 50%.
This report aims to provide a comprehensive presentation of the global market for Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar.
Report Scope
The Biosimilar market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilar market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Amgen
Biogen
Novartis
Samsung Bioepis
Viatris
Fresenius Kabi
Celltrion
Cadila Healthcare
Torrent Pharmaceuticals
Boehringer Ingelheim
Qilu Pharmaceutical
Bio-Thera
Zhejiang Hisun
Shanghai Henlius
Innovent Biologics
Jiangsu Hengrui
Gan&Lee
Tonghua Dongbao
United Laboratory
3SBIO
Luye Pharma
Segment by Type
Biosimilar Monoclonal Antibodies
Biosimilar Insulin
Others
Segment by Application
Cancer
Immunological Diseases
Diabetes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biosimilar companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biosimilar Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Biosimilar Monoclonal Antibodies
1.2.3 Biosimilar Insulin
1.2.4 Others
1.3 Market by Application
1.3.1 Global Biosimilar Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Cancer
1.3.3 Immunological Diseases
1.3.4 Diabetes
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biosimilar Market Perspective (2019-2030)
2.2 Biosimilar Growth Trends by Region
2.2.1 Global Biosimilar Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Biosimilar Historic Market Size by Region (2019-2024)
2.2.3 Biosimilar Forecasted Market Size by Region (2025-2030)
2.3 Biosimilar Market Dynamics
2.3.1 Biosimilar Industry Trends
2.3.2 Biosimilar Market Drivers
2.3.3 Biosimilar Market Challenges
2.3.4 Biosimilar Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biosimilar Players by Revenue
3.1.1 Global Top Biosimilar Players by Revenue (2019-2024)
3.1.2 Global Biosimilar Revenue Market Share by Players (2019-2024)
3.2 Global Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Biosimilar Revenue
3.4 Global Biosimilar Market Concentration Ratio
3.4.1 Global Biosimilar Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biosimilar Revenue in 2023
3.5 Biosimilar Key Players Head office and Area Served
3.6 Key Players Biosimilar Product Solution and Service
3.7 Date of Enter into Biosimilar Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Biosimilar Breakdown Data by Type
4.1 Global Biosimilar Historic Market Size by Type (2019-2024)
4.2 Global Biosimilar Forecasted Market Size by Type (2025-2030)
5 Biosimilar Breakdown Data by Application
5.1 Global Biosimilar Historic Market Size by Application (2019-2024)
5.2 Global Biosimilar Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Biosimilar Market Size (2019-2030)
6.2 North America Biosimilar Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Biosimilar Market Size by Country (2019-2024)
6.4 North America Biosimilar Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biosimilar Market Size (2019-2030)
7.2 Europe Biosimilar Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Biosimilar Market Size by Country (2019-2024)
7.4 Europe Biosimilar Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biosimilar Market Size (2019-2030)
8.2 Asia-Pacific Biosimilar Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Biosimilar Market Size by Region (2019-2024)
8.4 Asia-Pacific Biosimilar Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biosimilar Market Size (2019-2030)
9.2 Latin America Biosimilar Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Biosimilar Market Size by Country (2019-2024)
9.4 Latin America Biosimilar Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biosimilar Market Size (2019-2030)
10.2 Middle East & Africa Biosimilar Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Biosimilar Market Size by Country (2019-2024)
10.4 Middle East & Africa Biosimilar Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Biosimilar Introduction
11.1.4 Pfizer Revenue in Biosimilar Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Biosimilar Introduction
11.2.4 Amgen Revenue in Biosimilar Business (2019-2024)
11.2.5 Amgen Recent Development
11.3 Biogen
11.3.1 Biogen Company Detail
11.3.2 Biogen Business Overview
11.3.3 Biogen Biosimilar Introduction
11.3.4 Biogen Revenue in Biosimilar Business (2019-2024)
11.3.5 Biogen Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Biosimilar Introduction
11.4.4 Novartis Revenue in Biosimilar Business (2019-2024)
11.4.5 Novartis Recent Development
11.5 Samsung Bioepis
11.5.1 Samsung Bioepis Company Detail
11.5.2 Samsung Bioepis Business Overview
11.5.3 Samsung Bioepis Biosimilar Introduction
11.5.4 Samsung Bioepis Revenue in Biosimilar Business (2019-2024)
11.5.5 Samsung Bioepis Recent Development
11.6 Viatris
11.6.1 Viatris Company Detail
11.6.2 Viatris Business Overview
11.6.3 Viatris Biosimilar Introduction
11.6.4 Viatris Revenue in Biosimilar Business (2019-2024)
11.6.5 Viatris Recent Development
11.7 Fresenius Kabi
11.7.1 Fresenius Kabi Company Detail
11.7.2 Fresenius Kabi Business Overview
11.7.3 Fresenius Kabi Biosimilar Introduction
11.7.4 Fresenius Kabi Revenue in Biosimilar Business (2019-2024)
11.7.5 Fresenius Kabi Recent Development
11.8 Celltrion
11.8.1 Celltrion Company Detail
11.8.2 Celltrion Business Overview
11.8.3 Celltrion Biosimilar Introduction
11.8.4 Celltrion Revenue in Biosimilar Business (2019-2024)
11.8.5 Celltrion Recent Development
11.9 Cadila Healthcare
11.9.1 Cadila Healthcare Company Detail
11.9.2 Cadila Healthcare Business Overview
11.9.3 Cadila Healthcare Biosimilar Introduction
11.9.4 Cadila Healthcare Revenue in Biosimilar Business (2019-2024)
11.9.5 Cadila Healthcare Recent Development
11.10 Torrent Pharmaceuticals
11.10.1 Torrent Pharmaceuticals Company Detail
11.10.2 Torrent Pharmaceuticals Business Overview
11.10.3 Torrent Pharmaceuticals Biosimilar Introduction
11.10.4 Torrent Pharmaceuticals Revenue in Biosimilar Business (2019-2024)
11.10.5 Torrent Pharmaceuticals Recent Development
11.11 Boehringer Ingelheim
11.11.1 Boehringer Ingelheim Company Detail
11.11.2 Boehringer Ingelheim Business Overview
11.11.3 Boehringer Ingelheim Biosimilar Introduction
11.11.4 Boehringer Ingelheim Revenue in Biosimilar Business (2019-2024)
11.11.5 Boehringer Ingelheim Recent Development
11.12 Qilu Pharmaceutical
11.12.1 Qilu Pharmaceutical Company Detail
11.12.2 Qilu Pharmaceutical Business Overview
11.12.3 Qilu Pharmaceutical Biosimilar Introduction
11.12.4 Qilu Pharmaceutical Revenue in Biosimilar Business (2019-2024)
11.12.5 Qilu Pharmaceutical Recent Development
11.13 Bio-Thera
11.13.1 Bio-Thera Company Detail
11.13.2 Bio-Thera Business Overview
11.13.3 Bio-Thera Biosimilar Introduction
11.13.4 Bio-Thera Revenue in Biosimilar Business (2019-2024)
11.13.5 Bio-Thera Recent Development
11.14 Zhejiang Hisun
11.14.1 Zhejiang Hisun Company Detail
11.14.2 Zhejiang Hisun Business Overview
11.14.3 Zhejiang Hisun Biosimilar Introduction
11.14.4 Zhejiang Hisun Revenue in Biosimilar Business (2019-2024)
11.14.5 Zhejiang Hisun Recent Development
11.15 Shanghai Henlius
11.15.1 Shanghai Henlius Company Detail
11.15.2 Shanghai Henlius Business Overview
11.15.3 Shanghai Henlius Biosimilar Introduction
11.15.4 Shanghai Henlius Revenue in Biosimilar Business (2019-2024)
11.15.5 Shanghai Henlius Recent Development
11.16 Innovent Biologics
11.16.1 Innovent Biologics Company Detail
11.16.2 Innovent Biologics Business Overview
11.16.3 Innovent Biologics Biosimilar Introduction
11.16.4 Innovent Biologics Revenue in Biosimilar Business (2019-2024)
11.16.5 Innovent Biologics Recent Development
11.17 Jiangsu Hengrui
11.17.1 Jiangsu Hengrui Company Detail
11.17.2 Jiangsu Hengrui Business Overview
11.17.3 Jiangsu Hengrui Biosimilar Introduction
11.17.4 Jiangsu Hengrui Revenue in Biosimilar Business (2019-2024)
11.17.5 Jiangsu Hengrui Recent Development
11.18 Gan&Lee
11.18.1 Gan&Lee Company Detail
11.18.2 Gan&Lee Business Overview
11.18.3 Gan&Lee Biosimilar Introduction
11.18.4 Gan&Lee Revenue in Biosimilar Business (2019-2024)
11.18.5 Gan&Lee Recent Development
11.19 Tonghua Dongbao
11.19.1 Tonghua Dongbao Company Detail
11.19.2 Tonghua Dongbao Business Overview
11.19.3 Tonghua Dongbao Biosimilar Introduction
11.19.4 Tonghua Dongbao Revenue in Biosimilar Business (2019-2024)
11.19.5 Tonghua Dongbao Recent Development
11.20 United Laboratory
11.20.1 United Laboratory Company Detail
11.20.2 United Laboratory Business Overview
11.20.3 United Laboratory Biosimilar Introduction
11.20.4 United Laboratory Revenue in Biosimilar Business (2019-2024)
11.20.5 United Laboratory Recent Development
11.21 3SBIO
11.21.1 3SBIO Company Detail
11.21.2 3SBIO Business Overview
11.21.3 3SBIO Biosimilar Introduction
11.21.4 3SBIO Revenue in Biosimilar Business (2019-2024)
11.21.5 3SBIO Recent Development
11.22 Luye Pharma
11.22.1 Luye Pharma Company Detail
11.22.2 Luye Pharma Business Overview
11.22.3 Luye Pharma Biosimilar Introduction
11.22.4 Luye Pharma Revenue in Biosimilar Business (2019-2024)
11.22.5 Luye Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Biosimilar Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Biosimilar Monoclonal Antibodies
Table 3. Key Players of Biosimilar Insulin
Table 4. Key Players of Others
Table 5. Global Biosimilar Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Biosimilar Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Biosimilar Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Biosimilar Market Share by Region (2019-2024)
Table 9. Global Biosimilar Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Biosimilar Market Share by Region (2025-2030)
Table 11. Biosimilar Market Trends
Table 12. Biosimilar Market Drivers
Table 13. Biosimilar Market Challenges
Table 14. Biosimilar Market Restraints
Table 15. Global Biosimilar Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Biosimilar Market Share by Players (2019-2024)
Table 17. Global Top Biosimilar Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar as of 2023)
Table 18. Ranking of Global Top Biosimilar Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Biosimilar Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Biosimilar Product Solution and Service
Table 22. Date of Enter into Biosimilar Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Biosimilar Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Biosimilar Revenue Market Share by Type (2019-2024)
Table 26. Global Biosimilar Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Biosimilar Revenue Market Share by Type (2025-2030)
Table 28. Global Biosimilar Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Biosimilar Revenue Market Share by Application (2019-2024)
Table 30. Global Biosimilar Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Biosimilar Revenue Market Share by Application (2025-2030)
Table 32. North America Biosimilar Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Biosimilar Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Biosimilar Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Biosimilar Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Biosimilar Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Biosimilar Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Biosimilar Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Biosimilar Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Biosimilar Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Biosimilar Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Biosimilar Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Biosimilar Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Biosimilar Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Biosimilar Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Biosimilar Market Size by Country (2025-2030) & (US$ Million)
Table 47. Pfizer Company Detail
Table 48. Pfizer Business Overview
Table 49. Pfizer Biosimilar Product
Table 50. Pfizer Revenue in Biosimilar Business (2019-2024) & (US$ Million)
Table 51. Pfizer Recent Development
Table 52. Amgen Company Detail
Table 53. Amgen Business Overview
Table 54. Amgen Biosimilar Product
Table 55. Amgen Revenue in Biosimilar Business (2019-2024) & (US$ Million)
Table 56. Amgen Recent Development
Table 57. Biogen Company Detail
Table 58. Biogen Business Overview
Table 59. Biogen Biosimilar Product
Table 60. Biogen Revenue in Biosimilar Business (2019-2024) & (US$ Million)
Table 61. Biogen Recent Development
Table 62. Novartis Company Detail
Table 63. Novartis Business Overview
Table 64. Novartis Biosimilar Product
Table 65. Novartis Revenue in Biosimilar Business (2019-2024) & (US$ Million)
Table 66. Novartis Recent Development
Table 67. Samsung Bioepis Company Detail
Table 68. Samsung Bioepis Business Overview
Table 69. Samsung Bioepis Biosimilar Product
Table 70. Samsung Bioepis Revenue in Biosimilar Business (2019-2024) & (US$ Million)
Table 71. Samsung Bioepis Recent Development
Table 72. Viatris Company Detail
Table 73. Viatris Business Overview
Table 74. Viatris Biosimilar Product
Table 75. Viatris Revenue in Biosimilar Business (2019-2024) & (US$ Million)
Table 76. Viatris Recent Development
Table 77. Fresenius Kabi Company Detail
Table 78. Fresenius Kabi Business Overview
Table 79. Fresenius Kabi Biosimilar Product
Table 80. Fresenius Kabi Revenue in Biosimilar Business (2019-2024) & (US$ Million)
Table 81. Fresenius Kabi Recent Development
Table 82. Celltrion Company Detail
Table 83. Celltrion Business Overview
Table 84. Celltrion Biosimilar Product
Table 85. Celltrion Revenue in Biosimilar Business (2019-2024) & (US$ Million)
Table 86. Celltrion Recent Development
Table 87. Cadila Healthcare Company Detail
Table 88. Cadila Healthcare Business Overview
Table 89. Cadila Healthcare Biosimilar Product
Table 90. Cadila Healthcare Revenue in Biosimilar Business (2019-2024) & (US$ Million)
Table 91. Cadila Healthcare Recent Development
Table 92. Torrent Pharmaceuticals Company Detail
Table 93. Torrent Pharmaceuticals Business Overview
Table 94. Torrent Pharmaceuticals Biosimilar Product
Table 95. Torrent Pharmaceuticals Revenue in Biosimilar Business (2019-2024) & (US$ Million)
Table 96. Torrent Pharmaceuticals Recent Development
Table 97. Boehringer Ingelheim Company Detail
Table 98. Boehringer Ingelheim Business Overview
Table 99. Boehringer Ingelheim Biosimilar Product
Table 100. Boehringer Ingelheim Revenue in Biosimilar Business (2019-2024) & (US$ Million)
Table 101. Boehringer Ingelheim Recent Development
Table 102. Qilu Pharmaceutical Company Detail
Table 103. Qilu Pharmaceutical Business Overview
Table 104. Qilu Pharmaceutical Biosimilar Product
Table 105. Qilu Pharmaceutical Revenue in Biosimilar Business (2019-2024) & (US$ Million)
Table 106. Qilu Pharmaceutical Recent Development
Table 107. Bio-Thera Company Detail
Table 108. Bio-Thera Business Overview
Table 109. Bio-Thera Biosimilar Product
Table 110. Bio-Thera Revenue in Biosimilar Business (2019-2024) & (US$ Million)
Table 111. Bio-Thera Recent Development
Table 112. Zhejiang Hisun Company Detail
Table 113. Zhejiang Hisun Business Overview
Table 114. Zhejiang Hisun Biosimilar Product
Table 115. Zhejiang Hisun Revenue in Biosimilar Business (2019-2024) & (US$ Million)
Table 116. Zhejiang Hisun Recent Development
Table 117. Shanghai Henlius Company Detail
Table 118. Shanghai Henlius Business Overview
Table 119. Shanghai Henlius Biosimilar Product
Table 120. Shanghai Henlius Revenue in Biosimilar Business (2019-2024) & (US$ Million)
Table 121. Shanghai Henlius Recent Development
Table 122. Innovent Biologics Company Detail
Table 123. Innovent Biologics Business Overview
Table 124. Innovent Biologics Biosimilar Product
Table 125. Innovent Biologics Revenue in Biosimilar Business (2019-2024) & (US$ Million)
Table 126. Innovent Biologics Recent Development
Table 127. Jiangsu Hengrui Company Detail
Table 128. Jiangsu Hengrui Business Overview
Table 129. Jiangsu Hengrui Biosimilar Product
Table 130. Jiangsu Hengrui Revenue in Biosimilar Business (2019-2024) & (US$ Million)
Table 131. Jiangsu Hengrui Recent Development
Table 132. Gan&Lee Company Detail
Table 133. Gan&Lee Business Overview
Table 134. Gan&Lee Biosimilar Product
Table 135. Gan&Lee Revenue in Biosimilar Business (2019-2024) & (US$ Million)
Table 136. Gan&Lee Recent Development
Table 137. Tonghua Dongbao Company Detail
Table 138. Tonghua Dongbao Business Overview
Table 139. Tonghua Dongbao Biosimilar Product
Table 140. Tonghua Dongbao Revenue in Biosimilar Business (2019-2024) & (US$ Million)
Table 141. Tonghua Dongbao Recent Development
Table 142. United Laboratory Company Detail
Table 143. United Laboratory Business Overview
Table 144. United Laboratory Biosimilar Product
Table 145. United Laboratory Revenue in Biosimilar Business (2019-2024) & (US$ Million)
Table 146. United Laboratory Recent Development
Table 147. 3SBIO Company Detail
Table 148. 3SBIO Business Overview
Table 149. 3SBIO Biosimilar Product
Table 150. 3SBIO Revenue in Biosimilar Business (2019-2024) & (US$ Million)
Table 151. 3SBIO Recent Development
Table 152. Luye Pharma Company Detail
Table 153. Luye Pharma Business Overview
Table 154. Luye Pharma Biosimilar Product
Table 155. Luye Pharma Revenue in Biosimilar Business (2019-2024) & (US$ Million)
Table 156. Luye Pharma Recent Development
Table 157. Research Programs/Design for This Report
Table 158. Key Data Information from Secondary Sources
Table 159. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Biosimilar Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Biosimilar Market Share by Type: 2023 VS 2030
Figure 3. Biosimilar Monoclonal Antibodies Features
Figure 4. Biosimilar Insulin Features
Figure 5. Others Features
Figure 6. Global Biosimilar Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Biosimilar Market Share by Application: 2023 VS 2030
Figure 8. Cancer Case Studies
Figure 9. Immunological Diseases Case Studies
Figure 10. Diabetes Case Studies
Figure 11. Others Case Studies
Figure 12. Biosimilar Report Years Considered
Figure 13. Global Biosimilar Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Biosimilar Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Biosimilar Market Share by Region: 2023 VS 2030
Figure 16. Global Biosimilar Market Share by Players in 2023
Figure 17. Global Top Biosimilar Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Biosimilar Revenue in 2023
Figure 19. North America Biosimilar Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Biosimilar Market Share by Country (2019-2030)
Figure 21. United States Biosimilar Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Biosimilar Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Biosimilar Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Biosimilar Market Share by Country (2019-2030)
Figure 25. Germany Biosimilar Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Biosimilar Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Biosimilar Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Biosimilar Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Biosimilar Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Biosimilar Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Biosimilar Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Biosimilar Market Share by Region (2019-2030)
Figure 33. China Biosimilar Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Biosimilar Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Biosimilar Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Biosimilar Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Biosimilar Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Biosimilar Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Biosimilar Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Biosimilar Market Share by Country (2019-2030)
Figure 41. Mexico Biosimilar Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Biosimilar Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Biosimilar Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Biosimilar Market Share by Country (2019-2030)
Figure 45. Turkey Biosimilar Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Biosimilar Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Pfizer Revenue Growth Rate in Biosimilar Business (2019-2024)
Figure 48. Amgen Revenue Growth Rate in Biosimilar Business (2019-2024)
Figure 49. Biogen Revenue Growth Rate in Biosimilar Business (2019-2024)
Figure 50. Novartis Revenue Growth Rate in Biosimilar Business (2019-2024)
Figure 51. Samsung Bioepis Revenue Growth Rate in Biosimilar Business (2019-2024)
Figure 52. Viatris Revenue Growth Rate in Biosimilar Business (2019-2024)
Figure 53. Fresenius Kabi Revenue Growth Rate in Biosimilar Business (2019-2024)
Figure 54. Celltrion Revenue Growth Rate in Biosimilar Business (2019-2024)
Figure 55. Cadila Healthcare Revenue Growth Rate in Biosimilar Business (2019-2024)
Figure 56. Torrent Pharmaceuticals Revenue Growth Rate in Biosimilar Business (2019-2024)
Figure 57. Boehringer Ingelheim Revenue Growth Rate in Biosimilar Business (2019-2024)
Figure 58. Qilu Pharmaceutical Revenue Growth Rate in Biosimilar Business (2019-2024)
Figure 59. Bio-Thera Revenue Growth Rate in Biosimilar Business (2019-2024)
Figure 60. Zhejiang Hisun Revenue Growth Rate in Biosimilar Business (2019-2024)
Figure 61. Shanghai Henlius Revenue Growth Rate in Biosimilar Business (2019-2024)
Figure 62. Innovent Biologics Revenue Growth Rate in Biosimilar Business (2019-2024)
Figure 63. Jiangsu Hengrui Revenue Growth Rate in Biosimilar Business (2019-2024)
Figure 64. Gan&Lee Revenue Growth Rate in Biosimilar Business (2019-2024)
Figure 65. Tonghua Dongbao Revenue Growth Rate in Biosimilar Business (2019-2024)
Figure 66. United Laboratory Revenue Growth Rate in Biosimilar Business (2019-2024)
Figure 67. 3SBIO Revenue Growth Rate in Biosimilar Business (2019-2024)
Figure 68. Luye Pharma Revenue Growth Rate in Biosimilar Business (2019-2024)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
